Understanding SARS-CoV-2 and the drugs that might lessen its power
Modest improvements in treatment could make a big difference
THE INTERCONNECTEDNESS of the modern world has been a boon for SARS-CoV-2. Without planes, trains and automobiles the virus would never have got this far, this fast. Just a few months ago it took its first steps into a human host somewhere in or around Wuhan, in the Chinese province of Hubei. As of this week it had caused over 120,000 diagnosed cases of covid-19, from Tromsø to Buenos Aires, Alberta to Auckland, with most infections continuing to go undiagnosed (see article).
But interconnectedness may be its downfall, too. Scientists around the world are focusing their attention on its genome and the 27 proteins that it is known to produce, seeking to deepen their understanding and find ways to stop it in its tracks. The resulting plethora of activity has resulted in the posting of over 300 papers on MedRXiv, a repository for medical-research work that has not yet been formally peer-reviewed and published, since February 1st, and the depositing of hundreds of genome sequences in public databases. (For more coverage of covid-19 see our coronavirus hub.)
This article appeared in the Briefing section of the print edition under the headline "Anatomy of a killer"
More from Briefing
America’s $61bn aid package buys Ukraine time
It must use it wisely
America is uniquely ill-suited to handle a falling population
Which is a worry, because much of it is already shrinking
Homeowners face a $25trn bill from climate change
Property, the world’s biggest asset class, is also its most vulnerable